EMA Authorised: Bysumlog (insulin lispro) — Gan & Lee Pharmaceuticals Europe GmbH

View source ↗

Summary

The EMA has authorised Bysumlog (insulin lispro) for diabetes mellitus, under Gan & Lee Pharmaceuticals Europe GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Bysumlog (insulin lispro)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Gan & Lee Pharmaceuticals Europe GmbH. Decision date: 06/05/2026